ZDA
Zweig-DiMenna Associates’s Pacira BioSciences PCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-105,300
| Closed | -$4.3M | – | 125 |
|
|
2023
Q1 | $4.3M | Sell |
105,300
-34,750
| -25% | -$1.42M | 0.58% | 63 |
|
|
2022
Q4 | $5.41M | Hold |
140,050
| – | – | 0.79% | 49 |
|
|
2022
Q3 | $7.45M | Sell |
140,050
-24,200
| -15% | -$1.29M | 1.62% | 23 |
|
|
2022
Q2 | $9.58M | Sell |
164,250
-2,425
| -1% | -$141K | 1.82% | 18 |
|
|
2022
Q1 | $12.7M | Sell |
166,675
-28,325
| -15% | -$2.16M | 1.7% | 18 |
|
|
2021
Q4 | $11.7M | Buy |
195,000
+19,962
| +11% | +$1.2M | 0.95% | 46 |
|
|
2021
Q3 | $9.8M | Buy |
175,038
+2,500
| +1% | +$140K | 0.68% | 60 |
|
|
2021
Q2 | $10.5M | Sell |
172,538
-10,286
| -6% | -$624K | 0.63% | 65 |
|
|
2021
Q1 | $12.8M | Buy |
182,824
+44,500
| +32% | +$3.12M | 0.89% | 46 |
|
|
2020
Q4 | $8.28M | Buy |
138,324
+81,400
| +143% | +$4.87M | 0.52% | 66 |
|
|
2020
Q3 | $3.42M | Buy |
56,924
+15,000
| +36% | +$902K | 0.23% | 102 |
|
|
2020
Q2 | $2.2M | Buy |
+41,924
| New | +$2.2M | 0.23% | 91 |
|